These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 39047538)
1. Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Li J; Yang J; Jiang S; Tian Y; Zhang Y; Xu L; Hu B; Shi H; Li Z; Ran G; Huang Y; Ruan S Biomaterials; 2024 Dec; 311():122708. PubMed ID: 39047538 [TBL] [Abstract][Full Text] [Related]
2. Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma. Jiang S; Li W; Yang J; Zhang T; Zhang Y; Xu L; Hu B; Li Z; Gao H; Huang Y; Ruan S ACS Nano; 2024 Feb; 18(8):6445-6462. PubMed ID: 38358804 [TBL] [Abstract][Full Text] [Related]
3. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma. Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771 [TBL] [Abstract][Full Text] [Related]
4. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages. Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338 [TBL] [Abstract][Full Text] [Related]
5. Targeting MS4A4A: A novel pathway to improve immunotherapy responses in glioblastoma. Shao G; Cui X; Wang Y; Luo S; Li C; Jiang Y; Cai D; Li N; Li X CNS Neurosci Ther; 2024 Jul; 30(7):e14791. PubMed ID: 38997808 [TBL] [Abstract][Full Text] [Related]
6. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy. Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839 [TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970 [No Abstract] [Full Text] [Related]
8. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
9. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle. Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038 [TBL] [Abstract][Full Text] [Related]
11. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735 [TBL] [Abstract][Full Text] [Related]
12. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway. Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580 [No Abstract] [Full Text] [Related]
14. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605 [TBL] [Abstract][Full Text] [Related]
15. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy. Dang BN; Duwa R; Lee S; Kwon TK; Chang JH; Jeong JH; Yook S J Control Release; 2024 Aug; 372():587-608. PubMed ID: 38942083 [TBL] [Abstract][Full Text] [Related]
16. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
17. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
18. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound. Yang Q; Zhou Y; Chen J; Huang N; Wang Z; Cheng Y Int J Nanomedicine; 2021; 16():185-199. PubMed ID: 33447034 [TBL] [Abstract][Full Text] [Related]
19. Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy. Zou Y; Wang Y; Xu S; Liu Y; Yin J; Lovejoy DB; Zheng M; Liang XJ; Park JB; Efremov YM; Ulasov I; Shi B Adv Mater; 2022 Aug; 34(33):e2203958. PubMed ID: 35738390 [TBL] [Abstract][Full Text] [Related]
20. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy. Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]